Protalix Biotherapeutics (PLX) Stock Price, Quote & News

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 696 9345

Website: www.protalix.com

Address:

2 University Plaza, Suite 100, Hackensack, United States

brunoq14 Sep. 12 at 11:15 AM

$PLX Just ran PLX through the free Vectorvest analysis. Overall rating Very Good, Upside Potential Excellent, Recommendation Buy, Current Value $2.90, Safety Fair, Timing Very Good.

0 · Reply

Social_Idiot Sep. 12 at 2:49 AM

$PLX You know what it is? Dror finally realize he should not be public speaking so he kept it a little more personal and didn't share puclicly with questions. So it climbs. The Moshe Effect.

0 · Reply

brunoq14 Sep. 12 at 1:50 AM

$PLX Stock Consultant Breakthrough now called at 1.76, with estimated target price of 1.97. Hasn't been wrong so far.

0 · Reply

brunoq14 Sep. 12 at 1:31 AM

$PLX https://www.stockconsultant.com7consultnow/cgi.?symbol=PLX

0 · Reply

jcon777 Sep. 12 at 12:40 AM

$PLX Doing these two conferences within a few weeks is hopefully because management knows they're ready to grow significantly faster: Sept 8th H.C. Wainwright Investment Conf. Sept 16th Investor Summit Virtual

1 · Reply

Artfldgr Sep. 12 at 12:08 AM

$PLX Another 10% Someone knows something and it isn't us.

0 · Reply

jcon777 Sep. 11 at 11:13 PM

$PLX I asked chatgpt: "what are the chances that Elfabrio passes chmp for 4 week dosing Summary is: " ... chances at ~70‑80% in favor of CHMP approving the 4‑week regimen ..."

1 · Reply

Social_Idiot Sep. 11 at 11:10 PM

$PLX Held up despite the crash of other bios on my watchlist.

0 · Reply

Uktrader001 Sep. 11 at 9:11 PM

$PLX they love form 4 and 3 Mad Stock Option (Right to Buy) (1) 07/20/2035 Common Stock 597,990

0 · Reply

ed29 Sep. 11 at 5:41 PM

$PLX I am pretty sure shorts don't get nervous based on my experience : )

1 · Reply

Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 2, 2025, 6:50 AM EDT - 10 days ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 6:57 AM EDT - 18 days ago

Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp

Aug 14, 2025, 12:47 PM EDT - 4 weeks ago

Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 6:50 AM EDT - 4 weeks ago

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Aug 7, 2025, 12:53 PM EDT - 5 weeks ago

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Jul 21, 2025, 6:50 AM EDT - 7 weeks ago

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

Jun 30, 2025, 6:50 AM EDT - 2 months ago

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

May 14, 2025, 6:50 AM EDT - 4 months ago

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 9, 2025, 4:12 PM EDT - 4 months ago

Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript

May 9, 2025, 6:50 AM EDT - 4 months ago

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 5, 2025, 6:50 AM EDT - 4 months ago

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Apr 10, 2025, 9:54 AM EDT - 5 months ago

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline

Mar 24, 2025, 6:50 AM EDT - 6 months ago

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

Mar 17, 2025, 11:56 AM EDT - 6 months ago

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

Mar 17, 2025, 10:22 AM EDT - 6 months ago

Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:50 AM EDT - 6 months ago

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Mar 10, 2025, 6:50 AM EDT - 6 months ago

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

Feb 4, 2025, 6:50 AM EST - 7 months ago

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

Dec 23, 2024, 6:50 AM EST - 9 months ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Dec 9, 2024, 6:30 AM EST - 9 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Nov 14, 2024, 11:23 AM EST - 10 months ago

Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 6:50 AM EST - 10 months ago

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Nov 7, 2024, 6:50 AM EST - 11 months ago

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Oct 25, 2024, 7:18 AM EDT - 11 months ago

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Sep 16, 2024, 8:35 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

Sep 4, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

Aug 14, 2024, 10:32 AM EDT - 1 year ago

Protalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

Aug 7, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

Jun 13, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

May 29, 2024, 8:38 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the 2024 BIO International Convention

May 10, 2024, 11:13 AM EDT - 1 year ago

Protalix BioTherapeutics, Inc. (PLX) Q1 2024 Earnings Call Transcript

May 10, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results

May 3, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Mar 14, 2024, 1:02 PM EDT - 1 year ago

Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

Mar 7, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Feb 23, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Dec 26, 2023, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Nov 6, 2023, 11:57 AM EST - 2 years ago

Protalix Biotherapeutics, Inc. (PLX) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

Oct 30, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

Oct 9, 2023, 8:53 AM EDT - 2 years ago

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

CGEN KMDA TARO TEVA

Oct 9, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel

Sep 12, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

IMTX

Sep 6, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

brunoq14 Sep. 12 at 11:15 AM

$PLX Just ran PLX through the free Vectorvest analysis. Overall rating Very Good, Upside Potential Excellent, Recommendation Buy, Current Value $2.90, Safety Fair, Timing Very Good.

0 · Reply

Social_Idiot Sep. 12 at 2:49 AM

$PLX You know what it is? Dror finally realize he should not be public speaking so he kept it a little more personal and didn't share puclicly with questions. So it climbs. The Moshe Effect.

0 · Reply

brunoq14 Sep. 12 at 1:50 AM

$PLX Stock Consultant Breakthrough now called at 1.76, with estimated target price of 1.97. Hasn't been wrong so far.

0 · Reply

brunoq14 Sep. 12 at 1:31 AM

$PLX https://www.stockconsultant.com7consultnow/cgi.?symbol=PLX

0 · Reply

jcon777 Sep. 12 at 12:40 AM

1 · Reply

Artfldgr Sep. 12 at 12:08 AM

$PLX Another 10% Someone knows something and it isn't us.

0 · Reply

jcon777 Sep. 11 at 11:13 PM

$PLX I asked chatgpt: "what are the chances that Elfabrio passes chmp for 4 week dosing Summary is: " ... chances at ~70‑80% in favor of CHMP approving the 4‑week regimen ..."

1 · Reply

Social_Idiot Sep. 11 at 11:10 PM

$PLX Held up despite the crash of other bios on my watchlist.

0 · Reply

Uktrader001 Sep. 11 at 9:11 PM

$PLX they love form 4 and 3 Mad Stock Option (Right to Buy) (1) 07/20/2035 Common Stock 597,990

0 · Reply

ed29 Sep. 11 at 5:41 PM

$PLX I am pretty sure shorts don't get nervous based on my experience : )

1 · Reply

Artfldgr Sep. 11 at 5:32 PM

$PLX chatgpt on my musings.

1 · Reply

Artfldgr Sep. 11 at 5:09 PM

$PLX

0 · Reply

Artfldgr Sep. 11 at 5:07 PM

$PLX

0 · Reply

OldManLogan Sep. 11 at 5:07 PM

$PLX CHiMP meeting starts in 4 days... could be the reason for the renewed interest...

2 · Reply

Artfldgr Sep. 11 at 5:02 PM

$PLX Do note, that someone I THINK is accumulating, or more than once... take a look at the volume in the morning. what they appear to be doing is selling off to cause a drop, and hope to grab some shares from peoples stop loss that is too tight, or use those stop losses to drive price down, and collect the fruit. i noticed it playing with the charts, this is a 3m chart (day prices), with the one large buy cut out so as not to cloud the issue - forgive my line drawing, i dont have time to put up a better chart drawing software to show the channel. I had chat examine it too to kind of be sure... but in stocks, how sure can any one be?

0 · Reply

Plumberhouston Sep. 11 at 3:47 PM

$PLX Eyals Back September 11, 2025 PDF Version CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that Eyal Rubin, the Company's former Sr. Vice President and Chief Financial Officer, will present at the Investor Summit Virtual on September 16, 2025, updating investors about the Company's growth strategies and market opportunities. Event Details Event: Q3 Investor Summit Presentation Date: September 16, 2025 Presentation Time: 10:30 a.m. Eastern Daylight Time (EDT) Location: Webcast Link About Protalix BioTherapeutics, Inc. BioTherapeutics logo Linkedin Investors About Site Map Privacy Policy Terms of use© 2025 Protalix BioTherapeutics

1 · Reply

CliffordCapital Sep. 11 at 3:38 PM

$PLX touched the EMA200. Prob lil pullback but let‘s hope we finally start a new uptrend! 🫶🏼🙏🏻

0 · Reply

Plumberhouston Sep. 11 at 3:35 PM

$PLX Eyals Back https://ir.fluenceenergy.com/news-releases/news-release-details/fluence-begins-manufacturing-its-next-generation-smartstacktm

1 · Reply

ToRni27 Sep. 11 at 3:04 PM

$PLX low volume. Slowly grinding up. Are shorts getting any nervous? 3.7M shares are short. Will they add to their short position? 🤔

0 · Reply

Oystercwacker Sep. 11 at 3:02 PM

$CELV Shaking them Bushes... Time to fly soon with $PLX

0 · Reply

PRX102 Sep. 11 at 1:14 PM

$PLX My guess for Elfabrio Reg + commercial milestones ( just for fun) 2025- 25M (/ 35M?) 2026- 50M+ 2027- 75M+ 2028- 100M+ 2029- 100 to 125M 2030- 125 to 150M Above is based on the guidance from Eyal, of around $500M by 2030. Royalties separate, and expected to be 15-20%, maybe 25% market share for Chiesi by 2030

0 · Reply

brunoq14 Sep. 11 at 10:41 AM

$PLX One would think that at some point the large commercial milestones due by 2030 should become attractive to knowledgeable investors.

1 · Reply

Market Cap	134.75M
Revenue (ttm)	53.40M
Net Income (ttm)	2.93M
EPS (ttm)	N/A
PE Ratio	24.57
Forward PE	13.23
Profit Margin	5.49%
Debt to Equity Ratio	0.00

Volume	378,300
Avg Vol	620,388
Day's Range	N/A - N/A
Shares Out	79.73M
Stochastic %K	92%
Beta	-0.23
Analysts	Strong Sell
Price Target	$14.00